This Week’s Biopharma News: Big Moves in Bispecifics - Scorecard - MDSpire

This Week’s Biopharma News: Big Moves in Bispecifics

Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

  • June 9, 2026

  • 5 min

Share

Clinical Scorecard: This Week’s Biopharma News: Big Moves in Bispecifics

At a Glance

CategoryDetail
ConditionAdvanced squamous non-small cell lung cancer
Key MechanismsPD-1/VEGF bispecific antibody
Target PopulationPatients with advanced squamous NSCLC
Care SettingOncology

Key Highlights

  • median_survival_rates
  • adverse_events

Guideline-Based Recommendations

Diagnosis

    Management

    • Ivonescimab plus chemotherapy as first-line treatment for advanced squamous NSCLC based on HARMONi-6 trial results.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Adults with advanced squamous NSCLC.

        Ivonescimab shows significant survival benefits compared to standard therapies.

        Clinical Best Practices

        • Consider ivonescimab for patients not responding to standard PD-1 therapies.
        • Regularly assess patient response and adverse events during treatment, including specific monitoring for grade 3 or higher events.

        Related Resources & Content

        Original Source(s)

        This Week’s Biopharma News: Big Moves in Bispecifics

        • June 9, 2026

        Related Content

        Inside VIVEbiotech’s Work with Zelluna on TCR-NK Cell Therapy

        VIVEbiotech CEO Jon Alberdi lifts the lid on an eight-year collaboration focused on GMP lentiviral vectors for off-the-shelf solid tumor therapies

        • July 14, 2026

        • 4 min
        ESMO Breast Cancer 2026 Highlights Panel Discussion

        Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Erica L. Mayer, MD, MPH; Nancy Lin, MD; and Ana C. Garrido-Castro, MD discuss important breast cancer research presented at the 2026 ESMO Breast Cancer Congress.

        • June 26, 2026

        • 1 min
        ASCO26: Alicia Morgans, MD, MPH, ARACOG

        Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.

        • July 1, 2026

        • 1 min